Search Results - "Beers, Stephen A."

Influence of immunoglobulin isotype on therapeutic antibody function by Beers, Stephen A., Glennie, Martin J., White, Ann L.

“…Monoclonal antibody (mAb) therapeutics are revolutionizing cancer treatment; however, not all tumors respond, and agent optimization is essential to improve…”
Get full text

Fc-Engineering for Modulated Effector Functions-Improving Antibodies for Cancer Treatment by Liu, Rena, Oldham, Robert J, Teal, Emma, Beers, Stephen A, Cragg, Mark S

“…The majority of monoclonal antibody (mAb) therapeutics possess the ability to engage innate immune effectors through interactions mediated by their fragment…”
Get full text

The role of three-dimensional in vitro models in modelling the inflammatory microenvironment associated with obesity in breast cancer by Blyth, Rhianna Rachael Romany, Birts, Charles N, Beers, Stephen A

“…Abstract Obesity is an established risk factor for breast cancer in postmenopausal women. However, the underlying biological mechanisms of how obesity…”
Get full text

Conformation of the Human Immunoglobulin G2 Hinge Imparts Superagonistic Properties to Immunostimulatory Anticancer Antibodies by White, Ann L., Chan, H.T. Claude, French, Ruth R., Willoughby, Jane, Mockridge, C. Ian, Roghanian, Ali, Penfold, Christine A., Booth, Steven G., Dodhy, Ali, Polak, Marta E., Potter, Elizabeth A., Ardern-Jones, Michael R., Verbeek, J. Sjef, Johnson, Peter W.M., Al-Shamkhani, Aymen, Cragg, Mark S., Beers, Stephen A., Glennie, Martin J.

“…Monoclonal antibody (mAb) drugs that stimulate antitumor immunity are transforming cancer treatment but require optimization for maximum clinical impact. Here,…”
Get full text

Tri-Lineage Differentiation Potential of Osteosarcoma Cell Lines and Human Bone Marrow Stromal Cells from Different Anatomical Locations by Smith, Hannah L, Gray, Juliet C, Beers, Stephen A, Kanczler, Janos M

“…The bone cancer osteosarcoma, found mainly in adolescents, routinely forms around the growth plate/metaphysis of long bones. Bone marrow composition changes…”
Get full text

Discrepancies in the Tumor Microenvironment of Spontaneous and Orthotopic Murine Models of Pancreatic Cancer Uncover a New Immunostimulatory Phenotype for B Cells by Spear, Sarah, Candido, Juliana B, McDermott, Jacqueline R, Ghirelli, Cristina, Maniati, Eleni, Beers, Stephen A, Balkwill, Frances R, Kocher, Hemant M, Capasso, Melania

“…B cells are salient features of pancreatic ductal adenocarcinoma (PDAC) tumors, yet their role in this disease remains controversial. Murine studies have…”
Get full text

Activation of GABA(A) receptors inhibits T cell proliferation by Sparrow, Emma L, James, Sonya, Hussain, Khiyam, Beers, Stephen A, Cragg, Mark S, Bogdanov, Yury D

“…The major sites for fast synaptic inhibition in the central nervous system (CNS) are ion channels activated by γ-aminobutyric acid (GABA). These receptors are…”
Get full text

Novel type II anti-CD20 monoclonal antibody (GA101) evokes homotypic adhesion and actin-dependent, lysosome-mediated cell death in B-cell malignancies by Alduaij, Waleed, Ivanov, Andrei, Honeychurch, Jamie, Cheadle, Eleanor J., Potluri, Sandeep, Lim, Sean H., Shimada, Kazuyuki, Chan, Claude H.T., Tutt, Alison, Beers, Stephen A., Glennie, Martin J., Cragg, Mark S., Illidge, Tim M.

“…The anti-CD20 mAb rituximab has substantially improved the clinical outcome of patients with a wide range of B-cell malignancies. However, many patients…”
Get full text

Immune characterization of pre-clinical murine models of neuroblastoma by Webb, Emily R., Lanati, Silvia, Wareham, Carol, Easton, Alistair, Dunn, Stuart N., Inzhelevskaya, Tatyana, Sadler, Freja M., James, Sonya, Ashton-Key, Margaret, Cragg, Mark S., Beers, Stephen A., Gray, Juliet C.

“…Immunotherapy offers a potentially less toxic, more tumor-specific treatment for neuroblastoma than conventional cytotoxic therapies. Accurate and reproducible…”
Get full text

Fc gamma receptor IIb on target B cells promotes rituximab internalization and reduces clinical efficacy by Lim, Sean H., Vaughan, Andrew T., Ashton-Key, Margaret, Williams, Emily L., Dixon, Sandra V., Chan, H. T. Claude, Beers, Stephen A., French, Ruth R., Cox, Kerry L., Davies, Andrew J., Potter, Kathleen N., Mockridge, C. Ian, Oscier, David G., Johnson, Peter W.M., Cragg, Mark S., Glennie, Martin J.

“…The anti-CD20 mAb rituximab is central to the treatment of B-cell malignancies, but resistance remains a significant problem. We recently reported that…”
Get full text

Antagonistic Human FcγRIIB (CD32B) Antibodies Have Anti-Tumor Activity and Overcome Resistance to Antibody Therapy In Vivo by Roghanian, Ali, Teige, Ingrid, Mårtensson, Linda, Cox, Kerry L., Kovacek, Mathilda, Ljungars, Anne, Mattson, Jenny, Sundberg, Annika, Vaughan, Andrew T., Shah, Vallari, Smyth, Neil R., Sheth, Bhavwanti, Chan, H.T. Claude, Li, Zhan-Chun, Williams, Emily L., Manfredi, Giusi, Oldham, Robert J., Mockridge, C. Ian, James, Sonya A., Dahal, Lekh N., Hussain, Khiyam, Nilsson, Björn, Verbeek, J. Sjef, Juliusson, Gunnar, Hansson, Markus, Jerkeman, Mats, Johnson, Peter W.M., Davies, Andrew, Beers, Stephen A., Glennie, Martin J., Frendéus, Björn, Cragg, Mark S.

“…Therapeutic antibodies have transformed cancer therapy, unlocking mechanisms of action by engaging the immune system. Unfortunately, cures rarely occur and…”
Get full text

Antigenic modulation limits the efficacy of anti-CD20 antibodies: implications for antibody selection by Beers, Stephen A., French, Ruth R., Chan, H.T. Claude, Lim, Sean H., Jarrett, Timothy C., Vidal, Regina Mora, Wijayaweera, Sahan S., Dixon, Sandra V., Kim, Hyungjin, Cox, Kerry L., Kerr, Jonathan P., Johnston, David A., Johnson, Peter W.M., Verbeek, J. Sjef, Glennie, Martin J., Cragg, Mark S.

“…Rituximab, a monoclonal antibody that targets CD20 on B cells, is now central to the treatment of a variety of malignant and autoimmune disorders. Despite this…”
Get full text

Developing a 3D B Cell Lymphoma Culture System to Model Antibody Therapy by Foxall, Russell, Narang, Priyanka, Glaysher, Bridget, Hub, Elin, Teal, Emma, Coles, Mark C, Ashton-Key, Margaret, Beers, Stephen A, Cragg, Mark S

“…Diffuse large cell B cell lymphoma (DLBCL) accounts for approximately 30%-40% of all non-Hodgkin lymphoma (NHL) cases. Current first line DLBCL treatment…”
Get full text

Anti-CD20 monoclonal antibodies: historical and future perspectives by LIM, Sean H, BEERS, Stephen A, FRENCH, Ruth R, JOHNSON, Peter W. M, GLENNIE, Martin J, CRAGG, Mark S

“…Antibodies to CD20 have confirmed the hypothesis that monoclonal reagents can be given in vivo to alleviate human diseases. The targeting of CD20 on normal,…”
Get full text

CD20 as a Target for Therapeutic Type I and II Monoclonal Antibodies by Beers, Stephen A, Chan, Claude H.T, French, Ruth R, Cragg, Mark S, Glennie, Martin J

“…The last decade has seen the monoclonal antibody (mAb), rituximab, transform clinical management of many non-Hodgkin lymphomas and more recently provide new…”
Get full text

The Role of Pre-Clinical 3-Dimensional Models of Osteosarcoma by Smith, Hannah L, Beers, Stephen A, Gray, Juliet C, Kanczler, Janos M

“…Treatment for osteosarcoma (OS) has been largely unchanged for several decades, with typical therapies being a mixture of chemotherapy and surgery. Although…”
Get full text

Prognostic significance of crown-like structures to trastuzumab response in patients with primary invasive HER2 + breast carcinoma by Birts, Charles N., Savva, Constantinos, Laversin, Stéphanie A., Lefas, Alicia, Krishnan, Jamie, Schapira, Aron, Ashton-Key, Margaret, Crispin, Max, Johnson, Peter W. M., Blaydes, Jeremy P., Copson, Ellen, Cutress, Ramsey I., Beers, Stephen A.

“…Obesity can initiate, promote, and maintain systemic inflammation via metabolic reprogramming of macrophages that encircle adipocytes, termed crown-like…”
Get full text

The Biological Activity of Human CD20 Monoclonal Antibodies Is Linked to Unique Epitopes on CD20 by Teeling, Jessica L, Mackus, Wendy J. M, Wiegman, Luus J. J. M, van den Brakel, Jeroen H. N, Beers, Stephen A, French, Ruth R, van Meerten, Tom, Ebeling, Saskia, Vink, Tom, Slootstra, Jerry W, Parren, Paul W. H. I, Glennie, Martin J, van de Winkel, Jan G. J

“…We have previously defined a panel of fully human CD20 mAb. Most of these were unexpectedly efficient in their ability to recruit C1q to the surface of…”
Get full text

Increased circulating resistin levels in early-onset breast cancer patients of normal body mass index correlate with lymph node negative involvement and longer disease free survival: a multi-center POSH cohort serum proteomics study by Zeidan, Bashar, Manousopoulou, Antigoni, Garay-Baquero, Diana J, White, Cory H, Larkin, Samantha E T, Potter, Kathleen N, Roumeliotis, Theodoros I, Papachristou, Evangelia K, Copson, Ellen, Cutress, Ramsey I, Beers, Stephen A, Eccles, Diana, Townsend, Paul A, Garbis, Spiros D

“…Early-onset breast cancer (EOBC) affects about one in 300 women aged 40 years or younger and is associated with worse outcomes than later onset breast cancer…”
Get full text

Induction of Cytosolic Calcium Flux by CD20 Is Dependent upon B Cell Antigen Receptor Signaling by Walshe, Claire A., Beers, Stephen A., French, Ruth R., Chan, Claude H.T., Johnson, Peter W., Packham, Graham K., Glennie, Martin J., Cragg, Mark S.

“…The anti-CD20 monoclonal antibody (mAb) rituximab is now routinely used for the treatment of non-Hodgkins lymphoma and is being examined in a wide range of…”
Get full text